[Enkephalinase inhibitors and molecular study of the differences between active sites of enkephalinase and angiotensin-converting enzyme].
With the aim of producing an analgesia physiologically induced by endogenous opioids, several series of inhibitors of the degradation enzymes of enkephalins have been synthetized by using as a model, at the atomic level, the active site of thermolysin, a bacterial endopeptidase similar to enkephalinase. Thiorphan and retro-thiorphan are very potent inhibitors of enkephalinase (KI = 2 nM), but the retro compound is more selective, as it is unable to recognise the angiotensin conversion enzyme. Recently, a series of inhibitors containing a bidentate group were found to be capable of inhibiting the three metallopeptidases which break down the enkephalins. One of these compounds, kelatorphan, totally protects, in vitro and in vivo, Met-enkephalin from enzymatic degradation. Kelatorphan is the first complete inhibitor of enkephalin metabolism and is the only compound to possess an analgesic activity greater than that of a mixture of thiorphan and bestatin (non-specific aminopeptidase inhibitor). A tritiated derivative of kelatorphan has been used to visualise the enkephalinase in the rat brain by means of autoradiography. The enzyme has a heterogeneous distribution with a particularly high concentration in the nigro-striatal system.